Reason for request
Inclusion on the list of medicines approved for use by hospitals in the new indication: “treatment of multifocal motor neuropathy (MMN)”.
Clinical Benefit
| Substantial |
The actual benefit provided by TEGELINE in this indication is substantial. |
Clinical Added Value
| important |
The Transparency Committee considers that TEGELINE provides a substantial improvement in actual benefit (IAB II) in patients with multifocal motor neuropathy. |
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
AbakJWuKLzRZz3Tc
